Abstract:The management of inflammatory bowel diseases (IBD), has evolved significantly over the last decades. From an era when only corticosteroids and aminosalycilates were used in the eighties, passing through the administration of immunomodulators in the nineties and culminating in the use of biological agents such as infliximab (IFX) and adalimumab (ADA) in the late nineties and the beginning of this century, it is clear that even with the development of new drugs, remission rates still need to be improved in the … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.